Day 2
15th Biosimilars & Biologics World Congress 2025 Europe
The Evolution of Biologics & Biosimilars: Reducing Costs and Improving Accessibility
Hilton London Kensington, London, United Kingdom
Thursday 4th - Friday 5th September 2025
Niloofa Tabarra, Medical Liaison Dermatology Lead (Biosimilars), Amgen
PATIENT ACCESS AND AFFORDABILITY
- Understanding biologics and their market potential
- Developing a comprehensive go-to-market strategy
- Regulatory considerations for biologics
- Pricing and reimbursement strategies
Moderator:
Panelist:
- Opportunities, threats and policy changes that impact the UK market
- Moving from transactional to strategic approach is needed
- Dedicated Biosimilar strategy required
- Scaling up the relationship between Government And Industry
Mark Samuels, CEO, Medicines UK, CEO, British Biosimilars Association
- Biologics had contributed to improving clinical outcomes across wide range of disease
- Access to Biologics is still suboptimal in terms of overall access % and time of initiation
- Biosimilars should be further leveraged to address these major access gaps and not just to help saving health care spending
- Treatment guidelines should further emphasise the role of biosimilars and position them as first line Biologics to help maximising treatment outcomes.
Dr. Mourad F. Rezk, VP, Global Head, Medical & Development, Biogen
- Efficient pathways for biosimilar approval while maintaining rigorous standards for safety and efficacy.
- Fostering healthy market competition for biosimilars is vital to ensure affordability and wider access for patients
- The significant role of patients and healthcare professionals in driving biosimilar adoption.
Niloofa Tabarra, Medical Liaison Dermatology Lead (Biosimilars), Amgen
- A Discussion debate
Dr Jeremy Morais, Medical Director UK, Ireland & Nordics, Fresenius Kabi Ltd
Dr. Mourad F. Rezk, VP, Global Head, Medical & Development, Biogen
- An holistic viewpoint of the current state of biosimilar policy covering regulatory, market access and
intellectual property illustrating areas that require evolving to fully harness the value of biosimilars
globally for healthcare systems, patients and industry alike
Matthew Turner, Managing Director, External Affairs Consulting, former Senior Director
Government Affairs and Policy Biosimilars, Fresenius Kabi
- Easy market access. All biosimilars enters the hospital market Day One after patent expiryHigh uptake. Within a few weeks they have a market share of 90+%
- Increased patient care. Many more patients are now treated with biologic medicine – often 200+%
- Sustainable health care budgets. Hugh savings – close to 10% of the total medicines budget for just a few products
Peter Jørgensen, CEO, The Danish Generic & Biosimilar Medicines Association
- Impact of the U.S Biosecure Act and it’s future
- Impact of the U.S PILLS Act on Generic drugs industry
- How would the U.S policy on Most favoured nation status for drug pricing play out?
- Priorities for the new US FDA and its impact on drug development & market access
Bobby George, VP, Group Head Regulatory Affairs, Reliance Life Sciences
- Biosimilars have the potential to significantly reduce the cost of biologic medications, improving affordability and accessibility for patients.
- Increased competition in the biologics market, facilitated by biosimilars, can lead to greater access to essential medications for a wider range of patients.
- Biosimilars can contribute to improved health outcomes for individuals with chronic and life- threatening diseases.
Kalveer Flora, Pharmacy Lead, Rheumatology, London North West Healthcare NHS Trust
- Strategies for overcoming barriers to biosimilar adoption
- How can biosimilar developers, patients, healthcare professionals and payers conspire to establish a sustainable market
- Importance of Physician and Patients input in shaping international standards for biosimilars
- Policies in place to encourage physicians / pharmacist collaboration
- Commercial potential and best ways on how to gauge such an opportunity in biosimilar
Moderator:
Panelist:
Dr. Mourad F. Rezk, VP, Global Head, Medical & Development, Biogen
